Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $694.94M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 4.62M
Average 2.47M
PRME Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Prime Medicine, Inc.NASDAQ: PRME
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 28.3% from a year ago
Total equity stood at $76.7M at the end of Q1 FY2026, down 28.3% from a year earlier and down 36.5% from the prior quarter. Over 3 fiscal years it compounded at -27.4% a year.
Context
- Total equity amounted to 26.0% of total assets at the end of Q1 FY2026, down 6.6 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -28.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 120.87M USD
- Year-over-year change
- -21.1%
- 4-year CAGR
- -15.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 120.87M | -21.1% |
| FY2024 | 2024-12-31 | 153.15M | +15.1% |
| FY2023 | 2023-12-31 | 133.07M | -57.9% |
| FY2022 | 2022-12-31 | 316.27M | +32.0% |
| FY2021 | 2021-12-31 | 239.56M | — |
Total Equity vs competitors
How PRME compares with its peers on the latest reported figures
- PRME's Mar 2026 total equity of $76.7M is the 6th highest of the 7 companies compared; the peer median is $419.5M.
- Its year-over-year change of -28.3% is the 5th highest of 7, against a peer median of -17.2%.
- Total equity amounts to 26.0% of total assets for PRME, versus a peer median of 72.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.65B | -14.0% | +0.8% | 64.5% | |
| Jun 2026 | $1.07B | +2.0% | +19.1% | 77.0% | |
| Mar 2026 | $620.94M | -20.4% | -18.4% | 81.8% | |
| Mar 2026 | $218.05M | -4.3% | -13.4% | 94.6% | |
| Mar 2026 | $102.02M | -53.0% | -25.9% | 68.5% | |
| Mar 2026 | $76.7M | -28.3% | -27.4% | 26.0% | |
| Mar 2026 | $4.41M | -92.9% | -57.7% | 3.0% | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding PRME) | $419.5M | -17.2% | -15.9% | 72.7% | |
Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 185.42M | 187.62M | 41.57M | 182.48M | 63.03M |
| Short-term Investments | 84.2M | 106.3M | 80.09M | 7.97M | 114.65M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 246K | 2.25M | 14.67M | 3.61M |
| Total Current Assets | 270.58M | 296.62M | 142.98M | 211.89M | 181.29M |
| Property, Plant & Equipment (Net) | 15.68M | 48.55M | 36.6M | 71.56M | 146.75M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 15.6M | 15.14M | 14.28M | 14.06M | 14.69M |
| Total Non-current Assets | 31.28M | 63.7M | 50.88M | 85.62M | 161.44M |
| Total Assets | 301.86M | 360.31M | 193.85M | 297.51M | 342.73M |
| Account Payables | 1.44M | 4.33M | 19.54M | 11.35M | 8.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 7.09M | 7.82M |
| Other Current Liabilities | 14.66M | 6.98M | 10.91M | 6.93M | 9.04M |
| Total Current Liabilities | 57.98M | 26.71M | 56.42M | 37.96M | 37.45M |
| Long-term Debt | 0 | 0 | 0 | 0 | 108.29M |
| Deferred Tax Liabilities | 1.24M | 279K | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 63.22M | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 6M | 76.13M |
| Total Non-current Liabilities | 4.31M | 17.33M | 4.36M | 106.4M | 184.42M |
| Total Liabilities | 62.3M | 44.04M | 60.78M | 144.36M | 221.87M |
| Common Stock | 1K | 2K | 2K | 2K | 2K |
| Retained Earnings | (171.38M) | (293.2M) | (491.33M) | (687.21M) | (888.35M) |
| Accumulated OCI | (27K) | (384K) | (15K) | 1K | 82K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 239.56M | 316.27M | 133.07M | 153.15M | 120.87M |
| Total Debt | 10.41M | 28.75M | 13.63M | 40.79M | 116.43M |
| Net Debt | (175.01M) | (158.88M) | (27.94M) | (141.68M) | 53.4M |
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.